What is the main purpose of the new joint research agreement between Alivexis and Astellas Pharma?

The joint research aims to identify novel small-molecule compounds targeting drug discovery target molecules selected by Astellas, with the goal of creating innovative therapeutics.

When did Alivexis and Astellas Pharma enter into this second joint research agreement?

Alivexis and Astellas Pharma entered into this second joint research agreement on March 26, 2026.

What technology will Alivexis utilize in this joint research?

Alivexis will utilize its computational drug discovery platform, including ModBind™, for in silico evaluation and compound design, synthesis, and evaluation.

What is ModBind™ and what is its key capability?

ModBind™ is a physics-based simulation technology that rapidly and accurately predicts the binding affinity between small-molecule compounds and target proteins without experimental bioactivity data.

What rights will Astellas Pharma obtain from this joint research?

Astellas Pharma will obtain an option right to acquire rights to the research outcomes generated from this joint research.

AI News NQ Analysis

Alivexis Launches New Joint Drug Discovery Research with Astellas Pharma on Novel Drug Targets

NQ Score 56/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the main purpose of the new joint research agreement between Alivexis and Astellas Pharma?: A: The joint research aims to identify novel small-molecule compounds targeting drug discovery target molecules selected by Astellas, with the goal of creating innovative therapeutics.
Q: When did Alivexis and Astellas Pharma enter into this second joint research agreement?: A: Alivexis and Astellas Pharma entered into this second joint research agreement on March 26, 2026.
Q: What technology will Alivexis utilize in this joint research?: A: Alivexis will utilize its computational drug discovery platform, including ModBind™, for in silico evaluation and compound design, synthesis, and evaluation.
Q: What is ModBind™ and what is its key capability?: A: ModBind™ is a physics-based simulation technology that rapidly and accurately predicts the binding affinity between small-molecule compounds and target proteins without experimental bioactivity data.
Q: What rights will Astellas Pharma obtain from this joint research?: A: Astellas Pharma will obtain an option right to acquire rights to the research outcomes generated from this joint research.